Univ.-Prof. Mag. Dr. med. Andreas Widschwendter - Frauenheilkunde / Gynäkologie, Innsbruck - Publikationen

1. Widschwendner A: HPV - Screening. Jatros - Medizin für die Frau 2015.

2. Widschwendner A: Triage nach positiver HPV Testung. Gyn Aktiv 2015.

3. Dalla Torre D, Burtscher D, Edlinger M, Solder E, Widschwendter A, Rasse M, Puelacher W: Comparison of the prevalence of human papilloma virus infection in histopathologically confirmed premalignant oral lesions and healthy oral mucosa by brush smear detection. Oral Surg Oral Med Oral Pathol Oral Radiol 2015, 119(3):333-339.

4. Widschwendner A: Infektionen in der Gynäkologie. Apotheker 2013 2013.

5. Widschwendner A: Die Rolle des HPV beim Vulva- und Vaginalkarzinom. Wiener Medizinische Wochenschrift 2013.

6. Widschwendter A, Coban S, Mutz-Dehbalaie I, Hubalek M, Marth C, Fessler S: Recurrence of Condylomata acuminata: A retrospective long term study on 1800 women. Am J Obstet Gynecol 2012.

7. Widschwendner A: Evidenz für die Wirksamkeit der HPV Impfung. Krebshilfe 2012.

8. Mutz-Dehbalaie I, Egle D, Fessler S, Hubalek M, Fiegl H, Marth C, Widschwendter A: HE4 is an independent prognostic marker in endometrial cancer patients. Gynecol Oncol 2012.

9. Finkenstedt A, Widschwendter A, Brasse-Lagnel CG, Theurl I, Hubalek M, Dieplinger H, Tselepis C, Ward DG, Vogel W, Zoller H: Hepcidin is correlated to soluble hemojuvelin but not to increased GDF15 during pregnancy. Blood cells, molecules & diseases 2012.

10. Ehehalt D, Lener B, Pircher H, Dreier K, Pfister H, Kaufmann AM, Frangini S, Ressler S, Muller-Holzner E, Schmitt M et al: Detection of human papillomavirus type 18 e7 oncoprotein in cervical smears: a feasibility study. Journal of clinical microbiology 2012, 50(2):246-257.

11. Abudukadeer A, Bakry R, Goebel G, Mutz-Dehbalaie I, Widschwendter A, Bonn GK, Fiegl H: Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer Patients. Int J Mol Sci 2012, 13(7):8353-8363.

12. Dreier K, Scheiden R, Lener B, Ehehalt D, Pircher H, Muller-Holzner E, Rostek U, Kaiser A, Fiedler M, Ressler S et al: Subcellular localization of the human papillomavirus 16 E7 oncoprotein in CaSki cells and its detection in cervical adenocarcinoma and adenocarcinoma in situ. Virology 2011, 409(1):54-68.

13. Zuchna C, Hager M, Tringler B, Georgoulopoulos A, Ciresa-Koenig A, Volgger B, Widschwendter A, Staudach A: Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. Am J Obstet Gynecol 2010, 203(4):321 e321-326.

14. Aigner F, Conrad F, Widschwendter A, Zangerle R, Zelger B, Haidenberger A, Roka S, Heim K, Hopfl R, Klimpfinger M et al: [Anal HPV infections]. Wien Klin Wochenschr 2008, 120(19-20):631-641.

15. Aigner F, Conrad F, Widschwendter A, Zangerle R, Zelger B, Haidenberger A, Roka S, Heim K, Hopfl R, Klimpfinger M et al: Current concepts in anal HPV infection. Wien Klin Wochenschr 2008, 120(19-20):631-641.

16. Ressler S, Scheiden R, Dreier K, Laich A, Muller-Holzner E, Pircher H, Morandell D, Stein I, Viertler HP, Santer FR et al: High-risk human papillomavirus E7 oncoprotein detection in cervical squamous cell carcinoma. Clin Cancer Res 2007, 13(23):7067-7072.

17. Bonatti H, Aigner F, De Clercq E, Boesmueller C, Widschwendter A, Larcher C, Margreiter R, Schneeberger S: Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl Int 2007, 20(3):238-246.

18. Widschwendner A: Chronisch rezidivierende Vaginalmykosen. ÖÄZ 2005.

19. Heim K, Widschwendter A, Szedenik H, Geier A, Christensen ND, Bergant A, Concin N, Hopfl R: Specific serologic response to genital human papillomavirus types in patients with vulvar precancerous and cancerous lesions. Am J Obstet Gynecol 2005, 192(4):1073-1083.

20. Fiedler M, Ressler S, Campo-Fernandez B, Laich A, Jansen L, Widschwendter A, Viertler HP, Bacher N, Morandell D, Muller-Holzner E et al: Expression of the high-risk human papillomavirus type 18 and 45 E7 oncoproteins in cervical carcinoma biopsies. J Gen Virol 2005, 86(Pt 12):3235-3241.

21. Breitenecker GG, F. Joura, E. Kohlberger, P. Reich, O. Widschwendter, A.: Leitlinien für die Diagnose und Therapie von Cervikalen Intraepithelialen Neoplasien (CIN) und Mikrokarzinom der Cervix uteri. Speculum 2005, 23.

22. Widschwendter A, Muller HM, Hubalek MM, Wiedemair A, Fiegl H, Goebel G, Mueller-Holzner E, Marth C, Widschwendter M: Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol 2004, 93(2):407-416.

23. Widschwendter A, Muller HM, Fiegl H, Ivarsson L, Wiedemair A, Muller-Holzner E, Goebel G, Marth C, Widschwendter M: DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res 2004, 10(2):565-571.

24. Widschwendter A, Ivarsson L, Blassnig A, Muller HM, Fiegl H, Wiedemair A, Muller-Holzner E, Goebel G, Marth C, Widschwendter M: CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer 2004, 109(2):163-166.

25. Widschwendter A, Gattringer C, Ivarsson L, Fiegl H, Schneitter A, Ramoni A, Muller HM, Wiedemair A, Jerabek S, Muller-Holzner E et al: Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res 2004, 10(10):3396-3400.

26. Widschwendter A, Brunhuber T, Wiedemair A, Mueller-Holzner E, Marth C: Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. J Clin Virol 2004, 31(4):292-297.

27. Widschwendner A: Sinn und Unsinn der HPV Typisierung. Krebshilfe 2004.

28. Muller HM, Widschwendter A, Fiegl H, Goebel G, Wiedemair A, Muller-Holzner E, Marth C, Widschwendter M: A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. Cancer Lett 2004, 209(2):231-236.

29. Muller HM, Millinger S, Fiegl H, Goebel G, Ivarsson L, Widschwendter A, Muller-Holzner E, Marth C, Widschwendter M: Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem 2004, 50(11):2171-2173.

30. Muller HM, Ivarsson L, Schrocksnadel H, Fiegl H, Widschwendter A, Goebel G, Kilga-Nogler S, Philadelphy H, Gutter W, Marth C et al: DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem 2004, 50(6):1065-1068.

31. Muller HM, Fiegl H, Widschwendter A, Widschwendter M: Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci 2004, 1022:44-49.

32. Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, Muller HM, Goebel G, Mueller-Holzner E, Marth C, Spruck CH et al: Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene 2004, 23(23):4187-4192.

33. Galvan O, Joannidis M, Widschwendter A, Bonatti H, Sprinzl GM, Rehak P, Balogh D, Hackl JM: Comparison of different scoring methods for assessing the nutritional status of hospitalised patients. Wien Klin Wochenschr 2004, 116(17-18):596-602.

34. Fiegl H, Gattringer C, Widschwendter A, Schneitter A, Ramoni A, Sarlay D, Gaugg I, Goebel G, Muller HM, Mueller-Holzner E et al: Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 2004, 13(5):882-888.

35. Fiedler M, Muller-Holzner E, Viertler HP, Widschwendter A, Laich A, Pfister G, Spoden GA, Jansen-Durr P, Zwerschke W: High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. Faseb J 2004, 18(10):1120-1122.

36. Widschwendter A, Blassnig A, Wiedemair A, Muller-Holzner E, Muller HM, Marth C: Human papillomavirus DNA in sera of cervical cancer patients as tumor marker. Cancer Lett 2003, 202(2):231-239.

37. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003, 63(22):7641-7645.

38. Muller HM, Fiegl H, Goebel G, Hubalek MM, Widschwendter A, Muller-Holzner E, Marth C, Widschwendter M: MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br J Cancer 2003, 89(10):1934-1939.

39. Hopfl R, Petter A, Thaler P, Sarcletti M, Widschwendter A, Zangerle R: High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study. BMC Infect Dis 2003, 3:6.

40. Widschwendter A, Tonko-Geymayer S, Welte T, Daxenbichler G, Marth C, Doppler W: Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res 2002, 8(10):3065-3074.

41. Widschwendter A, Riha K, Duba HC, Kreczy A, Marth C, Schwarzler P: Prenatal diagnosis of de novo mosaic deletion 13q associated with multiple abnormalities. Ultrasound Obstet Gynecol 2002, 19(4):396-399.

42. Widschwendner A: HPV Infektion: Bedeutung, Diagnositk und Zukunftsaspekte. Update 2002.

43. Sehr P, Muller M, Hopfl R, Widschwendter A, Pawlita M: HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 2002, 106(1):61-70.

44. Heim K, Widschwendter A, Pirschner G, Wieland U, Awerkiew S, Christensen ND, Bergant A, Marth C, Hopfl R: Antibodies to human papillomavirus 16 L1 virus-like particles as an independent prognostic marker in cervical cancer. Am J Obstet Gynecol 2002, 186(4):705-711.

45. Hopfl R, Guger M, Widschwendter A: [Human papillomaviruses and their role in carcinogenesis]. Hautarzt 2001, 52(9):834-845; quiz 846-838.

46. Widschwendter M, Berger J, Hermann M, Muller HM, Amberger A, Zeschnigk M, Widschwendter A, Abendstein B, Zeimet AG, Daxenbichler G et al: Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst 2000, 92(10):826-832.

47. Hopfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B, Widschwendter A, Haimbuchner S, Muller-Holzner E, Pawlita M et al: Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000, 356(9246):1985-1986.

48. Widschwendter M, Widschwendter A, Welte T, Daxenbichler G, Zeimet AG, Bergant A, Berger J, Peyrat JP, Michel S, Doppler W et al: Retinoic acid modulates prolactin receptor expression and prolactin-induced STAT-5 activation in breast cancer cells in vitro. Br J Cancer 1999, 79(2):204-210.

49. Widschwendter M, Daxenbichler G, Culig Z, Michel S, Zeimet AG, Mortl MG, Widschwendter A, Marth C: Activity of retinoic acid receptor-gamma selectively binding retinoids alone and in combination with interferon-gamma in breast cancer cell lines. Int J Cancer 1997, 71(3):497-504.

50. Widschwendter M, Berger J, Daxenbichler G, Muller-Holzner E, Widschwendter A, Mayr A, Marth C, Zeimet AG: Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res 1997, 57(19):4158-4161.